{"ticker": {"uuid": "2c1758ce-a02e-47ef-b431-b60536a5b452", "symbol": "SMMT", "name": "Summit Therapeutics Inc.", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Summit Therapeutics schedules July 23 update on operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRDVxT2FheVNTWEpra0ltZnUtV3JGeUp5ajF4U0VJQTNod2dXT00wWjVKekgwNHlHUjJhS1BnY05HaTA2R1BSdm1wRUtteU9ub2pEOXR5MTJfTnA0dkN4T1ZVUjBxNm1RZVBEWmd0SHhmSDhMeEhwTi1xc0lybzVtTDZOUWM3bTF4OVV4Q0JoenZsTGs3cW5HVWNWRzRvRWZHNGwyUEJfcTdxbU9ySTNGaWVZVVZNMWRJQ2JrYQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPUm5WMzBaOXpQQ2NCVF9YMExZcHBQREVRTzF5aGpaMzd1dUpQYk9GRHpnMW9qN2o2dDZzUVMtR2lrRHhvSVNWZHg1OHQ5NGhWeDA4UW1BMl9nWU9GM09XQlI2Qm1LaG9SUWQ2V1UyTTV3Y1JraWZUeGJNcnFQN3Z1bTdDVWYwamFuZXd6UWtSYnBBbjRTeXZULS1vbWh6bkJOTWkxRTVrYUg4MUU4SUpGM3JKUTdlaXFJV3FVZEJvMF96X1dseVhjSHJqcmVxY1lBVFFOc1dlRDljYnUyMXpWaw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:23:06+00:00", "published_display": "13 Jul 2026 09:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNRk1SNkpGRV95bUZzMEVxQ1N3RGwwRm15a2dEY1ZyOXJvNFhDWFllT0pMU2JmbEJMQnpNd0YzQUwyYWR3WXk4SkU2N2h6aXRVbVNHTTctV3VXendPeVlRbUx3V0Y1eDEtWThrOVh6RFBnRkJOLWZuUFFwQ09rNzZQOEp3TnlRZ3Z2Zk0xZWJDZWZobGZZMVotS0hWQ0FPZw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMUM0amNmY0VXWFRyV3dsdldsQ1NPNlEwZkZzdHpjWnRUMGVaNmQtMUg2UjRyOG56WjAyWDFVNVZUcFMwTHR4YldEcTRxNFpGczZMMXluTWdpVEltQ1VDdUtrUUxaeWE3Yk55WjV6aHJJeXQxLS0ycE9TVWl0VGN1ZWtJTm13TVowbl9LdEZZRWNlRkxSbFFzdzFLWjVFcGZ0ZW44WEVsVQ?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVVnMUNQT0ZaUDNOVHB3djM1SVNDd3ViOWhSbGtvQ2tsakRVbWZRZGNvMHgzVFQyR2dEQVR5X3I1RW9jYm5QaXNZQjJnLTN2bVdzN1FYUEZudTByN24tUjNUY0dCOURMQ1hfX3JBdG1JU0t1SF9XOFZicVBONVk1YVo4REpZUVp4NUc3LU1WejdsZ3Y5RTllUTVtWlRrZTZuMUpzVko5MXlfeHNwMGpybDh6WmNWU3Iy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNeExRUzUzanNCaEVvLVh2Q0duSlBoYWxvRmRXR3RQeHpsTzJhYm11VXlnQ08zM0dVVnNVcV85WVpYMDRGeEdrMUl6a3lZcHlETkZEd2JScFlFNUhwcElTTEhwRU1wWUttbktBZ0hCaXc0c0hoZktNQWY4NjFsVy1RNDhFeG92MHFvVDgxdERYcFkyeWk4dW02UXVybmNCMW1GVV84?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNd0xiYmlwMVdwMTdmaEx3eXF0OXJNR29mWi02UmF2U3dveG5RRmJjczQ2dnJFZms5MXZnRk5tcHlUVjRvcnNBUmNHQ3NfdjJuOE1fdmZlOUd3OGJSejlXclJHTlRRdnFVNXhHbUFmZVZocXBkbE02SXo4S0JRZVIwLXI1YkRiT2hkZjU0V0std0JsZ1ZPSVQwQ2RwalByU0lqbnNlcERxTThOTXpNTHc?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxORWxsejRRZXNPeEhNYkNCR2t5bDhSUXBRSWNYMm1FTjB0ZVZsempQS1pTcUlsSmptQzZGNWI4Y1BnWWtYRTlWS2ZnSDdJYTdKZUdsY3hEbDF3WXhEdUcxbEhTcjN4dVVvSUVlTW1ZZFJkdUNGVjViYS1oQmEybEpXZ05naURmdUIxQVVjTmtBWnloNENzMlo1WVdnZHlnX0E?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNemwwcU02bURtV0hlQ0t4M0xfS3R3ZjlSSkZtSldONTZ1VjNCd1YxVU1SOWpNdnJLUXM4emtyMWhhVzBJYWdkdVF5YWtJUW5FYi1oVzZyOGVYNkptQ0M2YXJscUtxbTFBU1BKc29DVFBsQ0JtLXpqN3ktVDJqOUh0UFJBQTA2UUNoT0I3SmZOTXllWHB3U3RoaDI5WnJ2bHc?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQ2N3VlBYTmV6TVZyOHlKc1cwU29leWIzRzllVElTczV5Q2ZaZlh1MmV4MEVVdGtxdERJUEJtVmREdzd2UUxZXzFsVmQtVy1GR29ZVlNhV1NOd0NHbVpZdDVmV1VUNkh1US04U25iZDBTeXcxaGZqX2VLelVpcDFBZC1QcVJtWllNU2ItQkZzZkRvTTRyUDJDZmU3M2lONTJOeDZMcm5n?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNVHFNbzZrZWhpc05UeC1LeUNjbzhGd3JtV2xwVE5ycy1lbEhNX21IZExaVE9HLUliZ2dQZkhjdExqN3V5V3VTekN4eWZSMHhGcVhQRUhUYmlDMHNnSkxuY0ZVSVljbF9fZkRvQnJwS3JISkh5UFp0Nnd3b3I5cnl6YWlVVEY5cFFiVEhIV3FWOXM0a19xc1JzOF83QUp1ZXNTZlZydWRnYlpqRjlBZ2lUQjh2V0V6bFdUcmZVb3J6UVZBSE9Xdm5PU0NIWHRhZzFfLXV5aTFZTEVJOUU2Um82SmJnUG5LSzBa?oc=5", "source_name": "The AI Journal", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPV1ZvVTRBaXdqSGdUN3VBZ0NWS2JQZTdGU2NYcE82R1RpUzIzS0hXa1hmWnJqVm9RckFlN3FCdXVoUHpvYTZvOEo3SzRmWTUyV2NONjBqUnEzdF9uTlJBb0ktNTVfTHVWN2l4ZDV3VXFGY19TeDBUQkp1S1k1ME4xZ0hUUWZ2R3l5V05UcmZIeXdKWG94TjJjanptTFk0LWhJTkpBNjRETGMtYmZsMzhFX1ltRnNvRENlemtrRm9CUnJtWkJrLVc5Q0FPdmJ5QjhGWEpiYndScFhEVHo4MUNFSFdEbWZUMHJ4anp5M3lyZ0dvS1M1RU1wU0Fn?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Is in Talks for $15 Billion Partnership With AstraZeneca", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPaDQ5Y2c5ZmhKRFltbG9BN0tKSkFyZHlfa25lckxybGMwNXN0eDFpVUFFeEZLUm9UTGE4OEw3TmZxNHVsSHFzR0dBbXlLTUR3VHdZQTNZTDBOTlpianZZemx1YjEyVm9STDZuTnYtLTlnMDVNaXBYQWtoUW1xM0tsSE5Sa0hWZmpIMGtlWENZX3J4ZGF1R3NoS2dNcmZ4RW1xS1JzSGhsdU9uNk1TR2lLUnpR?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-07-03T07:00:00+00:00", "published_display": "03 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQLTBMa3NvWlAxRU0wak9uTXhGZm9SX1VDOWxDdTdsUmI1eGRVQ0NTakI5cFZjcnJIcEhRTlBTUm9SVVN4R2dPd1RpUnhyN3FRMlZnNkEtYmc4SWdCQXpvUUdLRW53eHByM1ZSQkUwcmx3WlFXWnROMGVLdFdTWnZCZVdtd2E5WW42aUVxNHhRU3FYUmw0NnZTU0xhZTBpc243VmY4V0d3dFMyOG94aTlmcm9wZDYtTmFYZjFDSHJDR2lXTC1NMlFyV1E5aVA5bVFIM0RiV1BuT21DOVQweHlMSXI0YTVQU1E?oc=5", "source_name": "BioSpace", "published_at": "2025-05-01T07:00:00+00:00", "published_display": "01 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRmphQ003ZVVqOXdmeWFpMUlfcXVYS1ZmTHY3dWhRREh1Vk5qYVhTanlDaXJvOEM0OHZSMUZ2SFhEZS1uOGFYWnJ0VC1JdXVjTFZJaWRFVnpfcnI4REFRU3lPd1ZMcmxFQ2RidzkxWXlwMGc2cHhLTXlwcFh3ZHZGOWlscUlYbXAtaU8wV054WEIwbXFhMl9YdndNUjYzcExYbHFsMDR4N0Vrem5ENkpLdXlXOGlrU0FQQ0ExZVoxTEZXTkxndy0yblZ5X3BRWnlkUldSTldPOGlYaVBuTDRxSEh5ZGN4NlVlWUJyeHNrSVItbXEwSkx1Y25n?oc=5", "source_name": "Business Wire", "published_at": "2024-07-25T07:00:00+00:00", "published_display": "25 Jul 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Raises $200 Million; Also Expands License Territories for Ivonescimab", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPcE1IQ2VaZ0d6RWctbzNEWmRRUFhDRV9zYThMTEJWSjNJbkplQjh0SE9rMFJvUXBKdUJtejNkUjEtZHJlMzlrX1BnUGhaVW51V3pHdUNjbzJjV3ZUcTg4YjdTUi0zeF83SURLMURtTUNVT3U4TkNNV29oLVNBU1kxLUhtMlZTQTJtNFplZ29faGU5X3JKUzFtUk1JVl8tbDNDYkh2a3ZHeWhSUDd1QWNSNVpDX2NhclRQS3JhYjJqd2Q1MTVaeURGQXZOQ1k2UVE?oc=5", "source_name": "Business Wire", "published_at": "2024-06-03T07:00:00+00:00", "published_display": "03 Jun 2024 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2022-12-06T08:00:00+00:00", "published_display": "06 Dec 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Summit Therapeutics schedules July 23 update on operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRDVxT2FheVNTWEpra0ltZnUtV3JGeUp5ajF4U0VJQTNod2dXT00wWjVKekgwNHlHUjJhS1BnY05HaTA2R1BSdm1wRUtteU9ub2pEOXR5MTJfTnA0dkN4T1ZVUjBxNm1RZVBEWmd0SHhmSDhMeEhwTi1xc0lybzVtTDZOUWM3bTF4OVV4Q0JoenZsTGs3cW5HVWNWRzRvRWZHNGwyUEJfcTdxbU9ySTNGaWVZVVZNMWRJQ2JrYQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPUm5WMzBaOXpQQ2NCVF9YMExZcHBQREVRTzF5aGpaMzd1dUpQYk9GRHpnMW9qN2o2dDZzUVMtR2lrRHhvSVNWZHg1OHQ5NGhWeDA4UW1BMl9nWU9GM09XQlI2Qm1LaG9SUWQ2V1UyTTV3Y1JraWZUeGJNcnFQN3Z1bTdDVWYwamFuZXd6UWtSYnBBbjRTeXZULS1vbWh6bkJOTWkxRTVrYUg4MUU4SUpGM3JKUTdlaXFJV3FVZEJvMF96X1dseVhjSHJqcmVxY1lBVFFOc1dlRDljYnUyMXpWaw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:23:06+00:00", "published_display": "13 Jul 2026 09:23", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNRk1SNkpGRV95bUZzMEVxQ1N3RGwwRm15a2dEY1ZyOXJvNFhDWFllT0pMU2JmbEJMQnpNd0YzQUwyYWR3WXk4SkU2N2h6aXRVbVNHTTctV3VXendPeVlRbUx3V0Y1eDEtWThrOVh6RFBnRkJOLWZuUFFwQ09rNzZQOEp3TnlRZ3Z2Zk0xZWJDZWZobGZZMVotS0hWQ0FPZw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMUM0amNmY0VXWFRyV3dsdldsQ1NPNlEwZkZzdHpjWnRUMGVaNmQtMUg2UjRyOG56WjAyWDFVNVZUcFMwTHR4YldEcTRxNFpGczZMMXluTWdpVEltQ1VDdUtrUUxaeWE3Yk55WjV6aHJJeXQxLS0ycE9TVWl0VGN1ZWtJTm13TVowbl9LdEZZRWNlRkxSbFFzdzFLWjVFcGZ0ZW44WEVsVQ?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVVnMUNQT0ZaUDNOVHB3djM1SVNDd3ViOWhSbGtvQ2tsakRVbWZRZGNvMHgzVFQyR2dEQVR5X3I1RW9jYm5QaXNZQjJnLTN2bVdzN1FYUEZudTByN24tUjNUY0dCOURMQ1hfX3JBdG1JU0t1SF9XOFZicVBONVk1YVo4REpZUVp4NUc3LU1WejdsZ3Y5RTllUTVtWlRrZTZuMUpzVko5MXlfeHNwMGpybDh6WmNWU3Iy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNeExRUzUzanNCaEVvLVh2Q0duSlBoYWxvRmRXR3RQeHpsTzJhYm11VXlnQ08zM0dVVnNVcV85WVpYMDRGeEdrMUl6a3lZcHlETkZEd2JScFlFNUhwcElTTEhwRU1wWUttbktBZ0hCaXc0c0hoZktNQWY4NjFsVy1RNDhFeG92MHFvVDgxdERYcFkyeWk4dW02UXVybmNCMW1GVV84?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNd0xiYmlwMVdwMTdmaEx3eXF0OXJNR29mWi02UmF2U3dveG5RRmJjczQ2dnJFZms5MXZnRk5tcHlUVjRvcnNBUmNHQ3NfdjJuOE1fdmZlOUd3OGJSejlXclJHTlRRdnFVNXhHbUFmZVZocXBkbE02SXo4S0JRZVIwLXI1YkRiT2hkZjU0V0std0JsZ1ZPSVQwQ2RwalByU0lqbnNlcERxTThOTXpNTHc?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxORWxsejRRZXNPeEhNYkNCR2t5bDhSUXBRSWNYMm1FTjB0ZVZsempQS1pTcUlsSmptQzZGNWI4Y1BnWWtYRTlWS2ZnSDdJYTdKZUdsY3hEbDF3WXhEdUcxbEhTcjN4dVVvSUVlTW1ZZFJkdUNGVjViYS1oQmEybEpXZ05naURmdUIxQVVjTmtBWnloNENzMlo1WVdnZHlnX0E?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNemwwcU02bURtV0hlQ0t4M0xfS3R3ZjlSSkZtSldONTZ1VjNCd1YxVU1SOWpNdnJLUXM4emtyMWhhVzBJYWdkdVF5YWtJUW5FYi1oVzZyOGVYNkptQ0M2YXJscUtxbTFBU1BKc29DVFBsQ0JtLXpqN3ktVDJqOUh0UFJBQTA2UUNoT0I3SmZOTXllWHB3U3RoaDI5WnJ2bHc?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQQ2N3VlBYTmV6TVZyOHlKc1cwU29leWIzRzllVElTczV5Q2ZaZlh1MmV4MEVVdGtxdERJUEJtVmREdzd2UUxZXzFsVmQtVy1GR29ZVlNhV1NOd0NHbVpZdDVmV1VUNkh1US04U25iZDBTeXcxaGZqX2VLelVpcDFBZC1QcVJtWllNU2ItQkZzZkRvTTRyUDJDZmU3M2lONTJOeDZMcm5n?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNVHFNbzZrZWhpc05UeC1LeUNjbzhGd3JtV2xwVE5ycy1lbEhNX21IZExaVE9HLUliZ2dQZkhjdExqN3V5V3VTekN4eWZSMHhGcVhQRUhUYmlDMHNnSkxuY0ZVSVljbF9fZkRvQnJwS3JISkh5UFp0Nnd3b3I5cnl6YWlVVEY5cFFiVEhIV3FWOXM0a19xc1JzOF83QUp1ZXNTZlZydWRnYlpqRjlBZ2lUQjh2V0V6bFdUcmZVb3J6UVZBSE9Xdm5PU0NIWHRhZzFfLXV5aTFZTEVJOUU2Um82SmJnUG5LSzBa?oc=5", "source_name": "The AI Journal", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPV1ZvVTRBaXdqSGdUN3VBZ0NWS2JQZTdGU2NYcE82R1RpUzIzS0hXa1hmWnJqVm9RckFlN3FCdXVoUHpvYTZvOEo3SzRmWTUyV2NONjBqUnEzdF9uTlJBb0ktNTVfTHVWN2l4ZDV3VXFGY19TeDBUQkp1S1k1ME4xZ0hUUWZ2R3l5V05UcmZIeXdKWG94TjJjanptTFk0LWhJTkpBNjRETGMtYmZsMzhFX1ltRnNvRENlemtrRm9CUnJtWkJrLVc5Q0FPdmJ5QjhGWEpiYndScFhEVHo4MUNFSFdEbWZUMHJ4anp5M3lyZ0dvS1M1RU1wU0Fn?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Is in Talks for $15 Billion Partnership With AstraZeneca", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPaDQ5Y2c5ZmhKRFltbG9BN0tKSkFyZHlfa25lckxybGMwNXN0eDFpVUFFeEZLUm9UTGE4OEw3TmZxNHVsSHFzR0dBbXlLTUR3VHdZQTNZTDBOTlpianZZemx1YjEyVm9STDZuTnYtLTlnMDVNaXBYQWtoUW1xM0tsSE5Sa0hWZmpIMGtlWENZX3J4ZGF1R3NoS2dNcmZ4RW1xS1JzSGhsdU9uNk1TR2lLUnpR?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-07-03T07:00:00+00:00", "published_display": "03 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQLTBMa3NvWlAxRU0wak9uTXhGZm9SX1VDOWxDdTdsUmI1eGRVQ0NTakI5cFZjcnJIcEhRTlBTUm9SVVN4R2dPd1RpUnhyN3FRMlZnNkEtYmc4SWdCQXpvUUdLRW53eHByM1ZSQkUwcmx3WlFXWnROMGVLdFdTWnZCZVdtd2E5WW42aUVxNHhRU3FYUmw0NnZTU0xhZTBpc243VmY4V0d3dFMyOG94aTlmcm9wZDYtTmFYZjFDSHJDR2lXTC1NMlFyV1E5aVA5bVFIM0RiV1BuT21DOVQweHlMSXI0YTVQU1E?oc=5", "source_name": "BioSpace", "published_at": "2025-05-01T07:00:00+00:00", "published_display": "01 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRmphQ003ZVVqOXdmeWFpMUlfcXVYS1ZmTHY3dWhRREh1Vk5qYVhTanlDaXJvOEM0OHZSMUZ2SFhEZS1uOGFYWnJ0VC1JdXVjTFZJaWRFVnpfcnI4REFRU3lPd1ZMcmxFQ2RidzkxWXlwMGc2cHhLTXlwcFh3ZHZGOWlscUlYbXAtaU8wV054WEIwbXFhMl9YdndNUjYzcExYbHFsMDR4N0Vrem5ENkpLdXlXOGlrU0FQQ0ExZVoxTEZXTkxndy0yblZ5X3BRWnlkUldSTldPOGlYaVBuTDRxSEh5ZGN4NlVlWUJyeHNrSVItbXEwSkx1Y25n?oc=5", "source_name": "Business Wire", "published_at": "2024-07-25T07:00:00+00:00", "published_display": "25 Jul 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Raises $200 Million; Also Expands License Territories for Ivonescimab", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPcE1IQ2VaZ0d6RWctbzNEWmRRUFhDRV9zYThMTEJWSjNJbkplQjh0SE9rMFJvUXBKdUJtejNkUjEtZHJlMzlrX1BnUGhaVW51V3pHdUNjbzJjV3ZUcTg4YjdTUi0zeF83SURLMURtTUNVT3U4TkNNV29oLVNBU1kxLUhtMlZTQTJtNFplZ29faGU5X3JKUzFtUk1JVl8tbDNDYkh2a3ZHeWhSUDd1QWNSNVpDX2NhclRQS3JhYjJqd2Q1MTVaeURGQXZOQ1k2UVE?oc=5", "source_name": "Business Wire", "published_at": "2024-06-03T07:00:00+00:00", "published_display": "03 Jun 2024 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2022-12-06T08:00:00+00:00", "published_display": "06 Dec 2022 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 76, "total_relevant": 17, "sentiment_summary": {"positive": 4, "negative": 0, "neutral": 13, "score": 55, "total": 17, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 7.15, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.9, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 290.12, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": 0.0, "twelve_week_move": -28.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.428413, "market_dynamics_buy_signal": false, "relative_strength": -20.174396, "fair_value_gap": -22.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 8.1042, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "Business Wire", "count": 2}, {"label": "DirectorsTalk Interviews", "count": 1}, {"label": "The AI Journal", "count": 1}, {"label": "Bloomberg.com", "count": 1}, {"label": "BioSpace", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 17}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 13}, {"label": "Earnings", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "17", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Summit Therapeutics schedules July 23 update on operations"}], "updated_at": "2026-07-21T21:08:03.599440+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}